All In Biotech

NDA 018963 · Bracco

Choletec

Technetium Tc-99m Mebrofenin Kit · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Sep 10, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Jan 21, 1987

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

92

31 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 29, 2025.

INDICATIONS AND USAGE Technetium Tc 99m Mebrofenin is indicated as a hepatobiliary imaging agent.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 21, 1987 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • CHOLETEC · TECHNETIUM TC-99M MEBROFENIN KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Mebrofenin Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug effect decreased34
  • multiple use of single-use product29
  • nausea10
  • hypersensitivity6
  • drug ineffective5
  • vomiting5
  • asthenia4
  • chills4
  • headache4
  • therapeutic response unexpected4
  • abdominal pain upper3
  • diarrhoea3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20053
20062
20077
20082
20095
20102
201313
201433
20153
20162
20171
20184
20194
20201
20211
20232
20265

Recalls

1 FDA enforcement reports for this application.

  • Aug 14, 2012 · Class III · Terminated

    Presence of Particulate Matter; potential for charcoal particulates

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.